ArticleFrontiers in cardiovascular medicine2026
Effects of dapagliflozin on myocardial motion parameters and cardiac electrophysiology in patients with type 2 diabetes Mellitus and coronary heart disease.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD) often coexist and exacerbate cardiac dysfunction. This study aimed to evaluate the effects of dapagliflozin on myocardial motion parameters and cardiac electrophysiology in patients with T2DM and CHD. Methods: This retrospective study included 262 patients with T2DM and CHD admitted between January 2021 and January 2025. Patients were assigned to either a conventional treatment group ( Results: Baseline characteristics were comparable between groups. The dapagliflozin group demonstrated superior clinical efficacy (93.60% vs. 76.64%, Conclusion: In patients with T2DM and CHD, adding dapagliflozin to conventional therapy improved cardiac function, myocardial performance, electrophysiological parameters, and exercise tolerance without increasing adverse cardiovascular events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.